Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors at 5 institutions in 2 countries.
William F PritchardCenter for Interventional Oncology, Radiology, and Imaging Sciences, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-5805-5344
John W KaranianCenter for Interventional Oncology, Radiology, and Imaging Sciences, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Chris JungfluidIQ Inc., Lewes, DE 19958, USA.
Ivane BakhutashviliCenter for Interventional Oncology, Radiology, and Imaging Sciences, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-3706-1491
Sheridan L ReedCenter for Interventional Oncology, Radiology, and Imaging Sciences, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-0320-5848
Matthew F StarostDivision of Veterinary Resources, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-6234-4875
Artemio MendozafluidIQ Inc., Lewes, DE 19958, USA.
David J EcksteinOffice of Clinical Research, Office of the Director, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-7023-7271
Bradford J WoodCenter for Interventional Oncology, Radiology, and Imaging Sciences, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-4297-0051
Andrew J MannesDepartment of Perioperative Medicine, NIH Clinical Center, National Institutes of Health, Bethesda MD 20892, USA.ORCID 0000-0001-5834-5667
Advanced Fluidics (United States) · USNational Institutes of Health Clinical Center · USNational Institutes of Health · USNational Disaster Medical Center · JPOffice of the Director · US
Funding
Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Target validation of novel therapeutic agents in mood disordersZIAMH002927 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2010 to 2025
$37.1M
Physiology, Psychology, and Genetics of ObesityZIAHD000641 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI YANOVSKI, JACK A. · 2009 to 2025
$24.8M
Center for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7M
Genetic Modifiers of Cancer RiskZIACP010142 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MIRABELLO, LISA · 2009 to 2025
$17.1M
Single-molecule sequence assembly and analysisZIAHG200398 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI PHILLIPPY, ADAM · 2016 to 2025
$15.9M
Inhibitors of Tyrosine Kinase-Dependent Signalling as Anti-Cancer AgentsZIABC006198 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BURKE, TERRENCE · 2009 to 2025
$13.7M
Risk prediction methodsZIACP010188 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBERT, PAUL · 2010 to 2025
$8.9M
Toxicology in the 21st Century Program (Tox21) - Systems ToxicologyZIATR000038 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI XIA, MENGHANG · 2015 to 2025
$5.7M
Toxicology in the 21st Century Program (Tox21) - Genomic ToxicologyZIATR000039 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI GERHOLD, DAVID · 2016 to 2025
$5.1M
Artificial Intelligence with Chest Imaging in COVID-19 and Isolation and Ventilator Devices for COVID-19ZIACL090072 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2020 to 2025
$0k
Interventional OncologyZIACL040015 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2009 to 2025
The COVID-19 pandemic demonstrated the need for inexpensive, easy-to-use, rapidly mass-produced resuscitation devices that could be quickly distributed in areas of critical need. In-line miniature ventilators based on principles of fluidics ventilate patients by automatically oscillating between forced inspiration and assisted expiration as airway pressure changes, requiring only a continuous supply of pressurized oxygen. Here, we designed three miniature ventilator models to operate in specific pressure ranges along a continuum of clinical lung injury (mild, moderate, and severe injury). Three-dimensional (3D)-printed prototype devices evaluated in a lung simulator generated airway pressures, tidal volumes, and minute ventilation within the targeted range for the state of lung disease each was designed to support. In testing in domestic swine before and after induction of pulmonary injury, the ventilators for mild and moderate injury met the design criteria when matched with the appropriate degree of lung injury. Although the ventilator for severe injury provided the specified design pressures, respiratory rate was elevated with reduced minute ventilation, a result of lung compliance below design parameters. Respiratory rate reflected how well each ventilator matched the injury state of the lungs and could guide selection of ventilator models in clinical use. This simple device could help mitigate shortages of conventional ventilators during pandemics and other disasters requiring rapid access to advanced airway management, or in transport applications for hands-free ventilation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
In-line miniature 3D-printed pressure-cycled ventilator maintains respiratory homeostasis in swine with induced acute pulmonary injury. · full record | OpenQuestion